Howell I, Howell A, Pavord ID. Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight. J Exp Med. 2023;220(7):e20221212.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025;13(1):23–34.

Article  CAS  PubMed  Google Scholar 

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report. 2024.

Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–42.

Article  PubMed  Google Scholar 

World Health Organization. Global health estimates 2021: Deaths by cause, age, sex, by country and by region, 2000-2021, Geneva WHO; 2024. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death. Accessed Sep 20 2025.

Momtazmanesh S, Moghaddam SS, Ghamari S-H, Rad EM, Rezaei N, Shobeiri P, et al. Global burden of chronic respiratory diseases and risk factors, 1990–2019: an update from the global burden of disease study 2019. eClinicalMedicine. 2023;59:101936.

Article  Google Scholar 

Chen S, Kuhn M, Prettner K, Yu F, Yang T, Bärnighausen T, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. Lancet Glob Health. 2023;11(8):e1183–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease–antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis. 2011;6:413–21.

Wechsler ME, Wells JM. What every clinician should know about inflammation in COPD. ERJ Open Res. 2024;10(5):00177–2024.

Article  PubMed  PubMed Central  Google Scholar 

Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med. 1996;154(4):1055–60.

Article  CAS  PubMed  Google Scholar 

Shapiro S. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans. 2002;30(2):98–102.

Article  CAS  PubMed  Google Scholar 

Dong L-L, Liu Z-Y, Chen K-J, Li Z-Y, Zhou J-S, Shen H-H, et al. The persistent inflammation in COPD: is autoimmunity the core mechanism? Eur Respir Rev. 2024;33:230137.

Article  PubMed  PubMed Central  Google Scholar 

Subedi S, Guntipally M, Suwal N, Thapa R, Bashyal S, Panth N, et al. Cellular senescence in chronic obstructive pulmonary disease: molecular mechanisms and therapeutic interventions. Ageing Res Rev. 2025;110:102813.

Article  CAS  PubMed  Google Scholar 

Sulaiman I, Wu BG, Chung M, Isaacs B, Tsay J-CJ, Holub M, et al. Lower airway dysbiosis augments lung inflammatory injury in mild-to-moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2023;208(10):1101–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019;54:1900651.

Article  CAS  PubMed  Google Scholar 

Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018;18(7):454–66.

Article  CAS  PubMed  Google Scholar 

Jubrail J, Kurian N, Niedergang F. Macrophage phagocytosis cracking the defect code in COPD. Biomed J. 2017;40(6):305–12.

Article  PubMed  PubMed Central  Google Scholar 

van der Vaart H, Koëter GH, Postma DS, Kauffman HF, ten Hacken NH. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(4):465–9.

Article  PubMed  Google Scholar 

Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, et al. TNFα antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142–8.

Article  PubMed  Google Scholar 

Rennard SI, Dale DC, Donohue JF, Kanniess F, Magnussen H, Sutherland ER, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1001–11.

Article  CAS  PubMed  Google Scholar 

Eich A, Urban V, Jutel M, Vlcek J, Shim JJ, Trofimov VI, et al. A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease. COPD: J Chron Obstruct Pulmon Dis. 2017;14(5):476–83.

Article  Google Scholar 

Calverley PM, Sethi S, Dawson M, Ward CK, Finch DK, Penney M, et al. A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res. 2017;18:1–12.

Article  Google Scholar 

Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3):926–34.

Article  CAS  PubMed  Google Scholar 

Kirsten A, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, et al. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther. 2015;31:36–41.

Article  CAS  PubMed  Google Scholar 

Maspero J, Adir Y, Al-Ahmad M, Celis-Preciado CA, Colodenco FD, Giavina-Bianchi P, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res. 2022;8(3):00576–2021.

Article  PubMed  PubMed Central  Google Scholar 

Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50.

Article  CAS  PubMed  Google Scholar 

Polverino F, Sin DD. Type 2 airway inflammation in COPD. Eur Respir J. 2024;63(5):2400150.

Article  CAS  PubMed  Google Scholar 

Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D. Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017;18:1–7.

Article  Google Scholar 

Rabe KF, Rennard S, Martinez FJ, Celli BR, Singh D, Papi A, et al. Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook. Am J Respir Crit Care Med. 2023;208(4):395–405.

Article  CAS  PubMed  Google Scholar 

Oshagbemi OA, Burden AM, Braeken DC, Henskens Y, Wouters EF, Driessen JH, et al. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am J Respir Crit Care Med. 2017;195(10):1402–4.

Article  PubMed  Google Scholar 

Jin J, Sunusi S, Lu H. Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated diseases and an essential therapeutic target. J Int Med Res. 2022;50(1):03000605211053156.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conroy DM, Williams TJ. Eotaxin and the attraction of eosinophils to the asthmatic lung. Respir Res. 2001;2:1–7.

Article  Google Scholar 

Couillard S, Pavord ID, Heaney LG, Petousi N, Hinks TS. Sub-stratification of type-2 high airway disease for therapeutic decision-making: a ‘bomb’ (blood eosinophils) meets ‘magnet’ (FeNO) framework. Respirology. 2022;27(8):573–7.

Article  PubMed  PubMed Central  Google Scholar 

Tiedeman C, Pavord IP. Understanding the relationship between eosinophils and chronic obstructive pulmonary disease: a new dawn? Forthcoming. 2025.

Blanchard C, Rothenberg ME. Biology of the eosinophil. Adv Immunol. 2009;101:81–121.

Article  CAS  PubMed  PubMed Central